6 citations · 12 across the 8 of their papers we have counts for
8 papers
Exhausting the type I error level in event-driven group-sequential designs with a closed testing procedure for progression-free and overall survival
Moritz Fabian Danzer, Kaspar Rufibach, Jan Beyersmann +1
In oncological clinical trials, overall survival (OS) is the gold-standard endpoint, but long follow-up and treatment switching can delay or dilute detectable effects. Progression-…
Correcting for sampling variability in maximum likelihood-based one-sample log-rank tests
Moritz Fabian Danzer, Rene Schmidt
Single-arm studies in the early development phases of new treatments are not uncommon in the context of rare diseases or in paediatrics. If an assessment of efficacy is to be made…
Confirmatory Adaptive Hypothesis Tests in Markovian Illness-Death Models
Rene Schmidt, Moritz Fabian Danzer
Classic adaptive designs for time-to-event trials are based on the log-rank statistic and its increments. Thereby, only information from the time-to-event endpoint on which the sel…
Adaptive weight selection for time-to-event data under non-proportional hazards
Moritz Fabian Danzer, Ina Dormuth
When planning a clinical trial for a time-to-event endpoint, we require an estimated effect size and need to consider the type of effect. Usually, an effect of proportional hazards…
Confirmatory adaptive group sequential designs for clinical trials with multiple time-to-event outcomes in Markov models
Moritz Fabian Danzer, Andreas Faldum, Thorsten Simon +2
The analysis of multiple time-to-event outcomes in a randomised controlled clinical trial can be accomplished with exisiting methods. However, depending on the characteristics of t…
A statistical framework for planning and analysing test-retest studies for repeatability of quantitative biomarker measurements
Moritz Fabian Danzer, Maria Eveslage, Dennis Görlich +1
There is an increasing number of potential biomarkers that could allow for early assessment of treatment response or disease progression. However, measurements of quantitative biom…
One-sample log-rank tests with consideration of reference curve sampling variability
Jannik Feld, Moritz Fabian Danzer, Andreas Faldum +1
The one-sample log-rank test is the method of choice for single-arm Phase II trials with time-to-event endpoint. It allows to compare the survival of the patients to a reference su…
On variance estimation for the one-sample log-rank test
Moritz Fabian Danzer, Andreas Faldum, Rene Schmidt
Time-to-event endpoints show an increasing popularity in phase II cancer trials. The standard statistical tool for such one-armed survival trials is the one-sample log-rank test. I…